Table 2

Logistic regression analysis of the risk factors for 28-day mortality in patients with adequate empirical therapy
Variable Univariate analysis P Multivariate analysis P
OR (95% CI) OR (95% CI)
Age 1.00 (0.96-1.04) .98
Male gender 0.48 (0.14-1.76) .27
Underlying disease
  Solid organ malignancy 1.22 (0.42-3.56) .71
  Hematologic malignancy 2.33 (0.84-6.46) .10
  Structural lung disease 0.25 (0.03-2.31) .22
  Neurologic disease 0.21 (0.02-1.81) .15
  Congestive heart failure 2.96 (0.26-34.42) .39
  Hemodialysis 0.69 (0.06-8.05) .77
  Immunosuppression 0.62 (0.20-1.93) .41
McCabe score
  Non-fatal 0.57 (0.09-3.38) .54
  Ultimately fatal 1.20 (0.24-6.11) .83
  Rapidly fatal 1.0 (referent)
APACHE II score 1.04 (0.97-1.11) .32
Pitt bacteremia score 1.21 (0.96-1.51) .10
CPIS 1.06 (0.73-1.54) .77
Type of pneumonia
  Community-acquired 1.00 (0.16-6.26) .99
  Healthcare-associated 0.74 (1.12-4.73) .75
  Hospital- acquired 1.02 (0.19-5.37) .98
  Ventilator-associated 1.0 (referent)
MDR-P. aeruginosa 0.43 (0.08-2.30) .32
Previous antibiotic therapy 1.42 (0.53-3.86) .49
Initial manifestation within 24 h
  Sepsis 0.36 (0.11-1.17) .09 0.07 (0.01-0.49) 0.008
  Severe sepsis 0.29 (0.07-1.21) .09 0.13 (0.02-0.89) 0.04
  Septic shock 1.0 (referent)
Type of adequate empirical therapy
  Monotherapy 0.38 (0.14-1.06) .06 0.05 (0.01-0.34) 0.002
  Combination therapy 1.0 (referent)

MDR = multidrug-resistant.

Park et al.

Park et al. BMC Infectious Diseases 2012 12:308   doi:10.1186/1471-2334-12-308

Open Data